Ocugen (OCGN) Price & Analysis

Compare

6,054 Followers

OCGN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.52 - $1.40

Previous CloseN/A

Volume1.89M

Average Volume (3M)5.41M

Market Cap

$279.15M

Enterprise Value$289.23M

Total Cash (Recent Filing)$37.80M

Total Debt (Recent Filing)$31.82M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Nov 07, 2025

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding292,304,750

10 Day Avg. Volume3,116,368

30 Day Avg. Volume5,409,611

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.04

Enterprise Value/Revenue63.96

Enterprise Value/Gross Profit63.96

Enterprise Value/Ebitda-5.32

Forecast

1Y Price Target

$6.33

Price Target Upside559.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe initiation of the OCU410ST pivotal GARDian3 study for Stargardt disease is progressing with patients already dosed, highlighting the company's active clinical development.

Financial PerformanceThe company reported higher than expected revenues and a lower net loss per share compared to consensus estimates, reflecting a positive financial performance.

Strategic MovesThe transaction is seen as a good strategic move that allows NeoCart to be valued separately while preserving Ocugen shareholders' interests.

Bears Say

Operational ClarityThere is limited insight into the terms of funds raise, complete design of pivotal study, and the management team that would be responsible for the development of NeoCart.

Ocugen News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Cardiff Oncology (CRDF) 38.29%...

7d ago

LAC

LQD

Ocugen reports Q2 EPS (5c), consensus (6c)

Reports Q2 revenue $1.37M, consensus $350,000. “While our modifier gene therapy clinical trials advance-now with two in late-stage-we...

7d ago

OCGN

Ocugen sees cash runway into 1Q26

The Company’s cash, cash equivalents, and restricted cash totaled $27.3 million as of June 30, 2025, compared to...

7d ago

OCGN

Ocugen signs term sheet for exclusive Korean rights to OCU400

Aligned with Ocugen’s (OCGN) business development strategy to pursue regional partnerships for OCU400, the Company signed a binding...

7d ago

OCGN

Options Volatility and Implied Earnings Moves Today, August 01, 2025

Today, several major companies are expected to report earnings: Bristol-Myers Squibb (BMY), Chevron (CVX), Dominion Energy (D), Enbridge...

7d ago

ABR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Draganfly (DPRO) 127.43% +1.80,...

10d ago

ACB

CNK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Blaize Holdings Inc (BZAI)...

16d ago

HLF

XOP

Ocugen announces new updates to its Retina SAB, Executive Leadership Team

Ocugen (OCGN) announced updates to its Retina Scientific Advisory Board, SAB, and Executive Leadership Team to enhance external...

18d ago

OCGN

Ocugen announces first patient dosed in Phase 2/3 GARDian3 trial for OCU410ST

Ocugen (OCGN) announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for...

21d ago

OCGN

Ocugen’s Growth Potential Highlighted by Pivotal Studies and Strong Financial Position

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen, with a...

4d ago

OCGN

Ocugen Reports Progress in Gene Therapy Trials

Ocugen Inc ( ($OCGN) ) has released its Q2 earnings. Here is a breakdown of the information Ocugen...

6d ago

OCGN

Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges

Ocugen Inc (($OCGN)) has held its Q2 earnings call. Read on for the main highlights of the call....

6d ago

OCGN

Ocugen Wins Dismissal of Securities Lawsuit

An update from Ocugen ( ($OCGN) ) is now available. On July 29, 2025, the U.S. District Court...

8d ago

OCGN

Is OCGN a Buy, Before Earnings?

Ocugen Inc (OCGN) is scheduled to report 2nd quarter earnings on 08/01/2025, before the market opens. Regarding Q2...

9d ago

OCGN

OCGN FAQ

What was Ocugen Inc’s price range in the past 12 months?

Ocugen Inc lowest stock price was $0.52 and its highest was $1.40 in the past 12 months.

What is Ocugen Inc’s market cap?

Ocugen Inc’s market cap is $279.15M.

When is Ocugen Inc’s upcoming earnings report date?

Ocugen Inc’s upcoming earnings report date is Nov 07, 2025 which is in 91 days.

How were Ocugen Inc’s earnings last quarter?

Ocugen Inc released its earnings results on Aug 01, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.056 by $0.006.

Is Ocugen Inc overvalued?

According to Wall Street analysts Ocugen Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ocugen Inc pay dividends?

Ocugen Inc does not currently pay dividends.

What is Ocugen Inc’s EPS estimate?

Ocugen Inc’s EPS estimate is -0.06.

How many shares outstanding does Ocugen Inc have?

Ocugen Inc has 292,304,750 shares outstanding.

What happened to Ocugen Inc’s price movement after its last earnings report?

Ocugen Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.056. Following the earnings report the stock price went down -3.883%.

Which hedge fund is a major shareholder of Ocugen Inc?

Currently, no hedge funds are holding shares in OCGN

Ocugen Stock Smart Score

Neutral

Fundamentals

Return on Equity

-569.99%

Trailing 12-Months

Asset Growth

32.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Ocugen (OCGN) Earnings & Revenues

Historic Earnings Reports

OCGN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Ocugen's earnings call highlighted significant progress in advancing their gene therapy platform with positive clinical trial results and strategic partnerships. However, financial challenges due to a decreased cash position and the need to secure additional funding were also noted. Overall, the positive advancements in their clinical programs and strategic partnerships outweigh the financial concerns.View all OCGN earnings summaries

OCGN Stock 12 Month Forecast

Average Price Target

$6.33

▲(559.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.99,1.5292307692307692,2.0684615384615386,2.6076923076923073,3.146923076923077,3.6861538461538457,4.225384615384615,4.764615384615384,5.303846153846154,5.843076923076923,6.382307692307692,6.921538461538461,7.46076923076923,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.99,1.4007692307692308,1.8115384615384615,2.2223076923076923,2.6330769230769233,3.043846153846154,3.4546153846153844,3.865384615384616,4.276153846153846,4.686923076923077,5.0976923076923075,5.508461538461539,5.9192307692307695,{"y":6.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.99,1.2215384615384615,1.4530769230769232,1.6846153846153846,1.916153846153846,2.1476923076923073,2.3792307692307695,2.6107692307692307,2.842307692307692,3.073846153846154,3.3053846153846154,3.5369230769230766,3.7684615384615388,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.39,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >